What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings?

Regulus Therapeutics Inc. (NASDAQ:RGLS) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Regulus Therapeutics in a research note issued on Wednesday, April 30th. Leerink Partnrs analyst J. Schwartz anticipates that the biopharmaceutical company will earn ($0.23) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Regulus Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Regulus Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.34) EPS and FY2026 earnings at ($1.06) EPS.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). During the same period in the prior year, the company posted ($0.40) EPS.

Several other research analysts also recently commented on the stock. Jones Trading reissued a “hold” rating and set a $7.00 price target (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $9.00 target price on shares of Regulus Therapeutics in a research note on Thursday. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $11.00 price target (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Friday, March 14th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.50.

Regulus Therapeutics Stock Performance

RGLS stock opened at $7.85 on Monday. Regulus Therapeutics has a 1-year low of $0.83 and a 1-year high of $8.20. The stock has a market cap of $520.01 million, a price-to-earnings ratio of -7.34 and a beta of 1.03. The company’s 50 day moving average is $2.11 and its 200 day moving average is $1.66.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter worth about $46,000. PEAK6 LLC purchased a new position in shares of Regulus Therapeutics during the fourth quarter valued at approximately $95,000. Oppenheimer & Co. Inc. purchased a new stake in Regulus Therapeutics in the first quarter worth $96,000. Velan Capital Investment Management LP purchased a new position in Regulus Therapeutics in the 4th quarter worth about $111,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.